Sana Biotechnology's SG293 shows strong preclinical results for in vivo CAR T therapy in blood cancers without chemotherapy.
Sana Biotechnology presented preclinical data for SG293, an in vivo CAR T cell therapy that targets CD8+ T cells to generate CD19-directed CAR T cells, showing potent and dose-dependent CAR T cell generation and deep B cell depletion in non-human pri...
